IL1B and atherosclerosis: The first outcome trial of colchicine in ASCVD was the Low Dose Colchicine for Secondary Prevention of Cardiovascular Disease (LoDoCo) study [7], a remarkably prescient investigation, published in 2013, before CANTOS had definitively demonstrated the causal relationship between IL-1β and adverse cardiovascular events.